Resources

What if there is an adjunct option in managing type 1 diabetes beyond insulin analogs in the form of GLP-1 RAs?

This review examines the differing arguments recent studies have made regarding blood pressure goals and cardiovascular risk. 

Tethered combination therapy for type 2 diabetes could be more beneficial than two medications taken concurrently.

CREDENCE trial shows that canagliflozin, an SGLT2 inhibitor, lowers the risk of cardiovascular and renal events in patients with T2DM, regardless of prior history of heart failure. 

Additional benefits are observed with dose escalation of semaglutide for patients with type 2 diabetes.

Sexual health questionnaires can be used as an early detection tool for men's CVD, coronary heart disease, stroke, and T2D.  

People with diabetes are more sensitive to increased inflammatory response, contributing to a fast spread of COVID-19 infection. 

Canagliflozin, an SGLT2 inhibitor, and its impact in reducing hospitalizations and health care costs in people with type 2 diabetes.

Metformin's primary safety concern in patients with impaired renal function is its ability to cause lactic acidosis. 

Systemic review shows sex, age, comorbid conditions, insulin use, and several out-of-range lab predictors on hospital admission, all play a role in COVID-19 severity.